ProCE Banner Activity

CCO Think Tank on Emerging HER2-Targeted ADCs: Gastrointestinal Malignancies


Slides from Zev A. Wainberg, MD, covering the recent developments in HER2 testing, clinical trial results for anti-HER2 antibody–drug conjugate (ADC) therapy, and current strategies for managing the safety profile of ADCs.

Released: March 20, 2024

Expiration: March 19, 2025



Zev A. Wainberg

Zev A. Wainberg, MD

Co-Director, GI Oncology Program
Professor of Medicine and Surgery
Director, Early Phase Therapeutics
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.


Daiichi Sankyo, Inc.